Code intelligence

FDA-NDA050817 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-NDA050817.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical

Critical

100%

High

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: CEFEPIME (CEFEPIME) — Type 3 - New Dosage Form

Policy FDA-NDA050817 · Infectious Disease

Critical

Baxter Healthcare's new dosage form of cefepime (injectable, NDA050817) follows the Part B billing pathway, consistent with its intravenous/injection route of administration typically administered in

View alert